Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02534805 · ClinicalTrials.gov registry record

Patient Buddy App for the Prevention of Avoidable Readmission in Cirrhosis

A clinical trial, sponsored by Virginia Commonwealth University.

Completed
Registry status
232
Enrollment target

NCT02534805: Completed study, sponsored by Virginia Commonwealth University.

NCT02534805 is a clinical trial that has completed, run by Virginia Commonwealth University. The registered enrollment target is 232 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02534805 has completed, sponsored by Virginia Commonwealth University.

COMPLETED
Registry status
232 participants
Enrollment target

Study Summary

To use the PatientBuddy App to reduce 30-day avoidable readmissions in cirrhotic patients using a patient and caregiver perspective.

Primary Outcome

Avoidable Readmissions within 30 days.

Trial Details

FieldValue
Enrollment Target 232 participants
Start Date 2015-08
Est. Completion 2017-01
Virginia Commonwealth University

558 total trials

What the finished NCT02534805 record still lists

NCT02534805 is an observational study that tracks outcomes without assigning an intervention. The registered 232 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 0 interventions.

NCT02534805 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02534805 about?

NCT02534805 is a clinical study titled "Patient Buddy App for the Prevention of Avoidable Readmission in Cirrhosis". To use the PatientBuddy App to reduce 30-day avoidable readmissions in cirrhotic patients using a patient and caregiver perspective.

What is the current status of trial NCT02534805?

This trial is currently completed. The enrollment target is 232 participants. The study started on 2015-08. Estimated completion is 2017-01.

Who is sponsoring clinical trial NCT02534805?

This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01356290 · 232 participants · Phase 2

    Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors

  • NCT04753359 · 232 participants · NA

    Mediterranean Diet and Weight Loss: Targeting the Bile Acid/Gut Microbiome Axis to Reduce Colorectal Cancer

  • NCT04770870 · 232 participants · NA

    Post Approval Study2: Hintermann Series H3 Total Ankle Replacement System

  • NCT05948943 · 232 participants · Phase 2

    Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02534805, the US trial registry maintained by the National Library of Medicine. NCT02534805 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.